Table 2. The relationship between general inflammatory infiltrate and clinico-pathological characteristics of patients with primary operable invasive ductal breast cancer.
| Low-grade inflammatory cell infiltrate (n=21) | High-grade inflammatory cell infiltrate (n=306) | (P-value) | |
|---|---|---|---|
| Age (⩽50/>50 years) |
3/18 |
88/218 |
0.153 |
| Size (⩽20/21–50/>50 mm) |
14/7/0 |
167/129/9 |
0.233 |
| Grade (I/II/III) |
6/12/3 |
53/116/137 |
0.013 |
| Involved lymph node (0/1–3/>3) |
12/6/3 |
152/91/59 |
0.491 |
| Oestrogen-receptor status (ER−/ER+) |
0/21 |
111/193 |
0.001 |
| Progesterone-receptor status (PR−/PR+) |
7/14 |
168/134 |
0.048 |
| HER-2 status (HER-2−/HER-2+) |
18/3 |
248/54 |
0.677 |
| Ki-67 status (Low Ki-67/high Ki-67) |
16/5 |
220/83 |
0.721 |
| Lymphovascular invasion (Absent/present) |
14/6 |
128/122 |
0.106 |
|
Innate immune response | |||
| Tumour neutrophil infiltrate (median, range) | 0 (0–20) | 0 (0–40) | 0.004 |
| Tumour macrophage infiltrate (median, range) |
119 (16–450) |
187 (34–619) |
<0.001 |
|
Adaptive immune response | |||
| Tumour lymphocyte infiltrate (median, range) | 0 | 98 (0–100) | <0.001 |
| Tumour plasma cell infiltrate (median, range) | 0 | 1 (0–90) | <0.001 |
| Tumour CD4+ T-lymphocytic infiltrate (median, range) | 5 (0–40) | 9 (0–425) | 0.054 |
| Tumour CD8+ T-lymphocytic infiltrate (median, range) | 10 (0–52) | 42 (0–342) | 0.001 |
| Tumour CD20+ B-lymphocytic infiltrate (median, range) | 0 (0–7) | 1 (0–328) | 0.001 |
| Tumour CD138+ B-lymphocytic infiltrate (median, range) | 0 (0–7) | 1 (1–235) | 0.187 |
| Loco-regional treatment (Lumpectomy+radiotherapy/mastectomy+radiotherapy) | 8/13 | 107/199 | 0.772 |
| Systemic treatment (ER-based treatment) (hormonal/hormonal+chemotherapy/chemotherapy/none) | 14/5/1/1 | 152/70/66/12 | 0.125 |
| Cancer-specific survival (months)a | 113 (78–148) | 150 (143–156) | 0.005 |
a
Mean (95%CI).